Cetuximab in squamous cell head and neck carcinomas

Vittorio Gebbia, F. Giuliani, V. M. Valori, R. Agueli, G. Colucci, E. Maiello

Research output: Contribution to journalArticlepeer-review


The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in advanced head and neck cancer.

Original languageEnglish
JournalAnnals of Oncology
Issue numberSUPPL. 6
Publication statusPublished - Jun 2007


  • Cetuximab
  • Chemotherapy
  • EGFR
  • Head and neck cancer
  • Patient outcome
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Cetuximab in squamous cell head and neck carcinomas'. Together they form a unique fingerprint.

Cite this